Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAFIR-ABC10 in Advanced Biliary Cancer
NCT05615818Phase 3Recruiting
- Sponsor
- Unicancer
- Start
- Jul 2024
- Primary completion
- Jun 2027
- Modality
- Fragment-Derived Small Molecules, Antibody Conjugates, Reversible Covalent Inhibitors
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of futibatinib, ivosidenib, zanidatamab, trastuzumab, neratinib and 3 more in biliary tract cancer (BTC) (2 arms), sponsored by Unicancer. Primary endpoint: Progression-free survival up to 5 years. Started Jul 2024; status: recruiting.
02
Drugs
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT05615818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05615818.